Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -82.32% is 227% below its 5-year average of -25.16%, near the low end of its 5-year range (-82.32%–-2.77%).
936.78% below its 12-month average of -7.94%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.43%.
RETURN ON ASSETS (ROA)
-82.32%
RETURN ON ASSETS (ROA) AVG TTM
-7.94%
RETURN ON ASSETS (ROA) AVG 3Y
-19.90%
RETURN ON ASSETS (ROA) AVG 5Y
-25.16%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-936.78%
CURRENT VS 3Y AVG
-313.72%
CURRENT VS 5Y AVG
-227.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.11%
median of 604 covered companies
CURRENT VS SECTOR MEDIAN
-182.79%
vs the sector median at left
Mirum Pharmaceuticals, Inc.
Market Cap
$4.82B
Return on Assets (ROA)
-82.32%
TTM Avg
-7.94%
3Y Avg
-19.90%
5Y Avg
-25.16%
Market Cap
$4.89B
Return on Assets (ROA)
-66.02%
TTM Avg
-31.80%
3Y Avg
-35.60%
5Y Avg
-41.38%
Market Cap
$4.73B
Return on Assets (ROA)
-2.47%
TTM Avg
-26.65%
3Y Avg
-27.96%
5Y Avg
-27.52%
Market Cap
$4.69B
Return on Assets (ROA)
4.59%
TTM Avg
-6.29%
3Y Avg
-18.57%
5Y Avg
-18.57%
Market Cap
$4.64B
Return on Assets (ROA)
2.32%
TTM Avg
-1.14%
3Y Avg
-5.25%
5Y Avg
-6.57%
Market Cap
$4.61B
Return on Assets (ROA)
-31.79%
TTM Avg
-38.86%
3Y Avg
-47.00%
5Y Avg
-47.76%
Market Cap
$5.04B
Return on Assets (ROA)
-78.04%
TTM Avg
-72.67%
3Y Avg
-59.05%
5Y Avg
-50.29%
Market Cap
$5.07B
Return on Assets (ROA)
5.08%
TTM Avg
4.88%
3Y Avg
4.58%
5Y Avg
3.44%
Market Cap
$5.09B
Return on Assets (ROA)
-45.20%
TTM Avg
-56.55%
3Y Avg
-55.28%
5Y Avg
-47.01%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | $4.82B | -82.32% | -7.94% | -19.90% | -25.16% |
| Erasca, Inc. (ERAS)vs › | $4.89B | -66.02% | -31.80% | -35.60% | -41.38% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.73B | -2.47% | -26.65% | -27.96% | -27.52% |
| BillionToOne, Inc. (BLLN)vs › | $4.69B | 4.59% | -6.29% | -18.57% | -18.57% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.64B | 2.32% | -1.14% | -5.25% | -6.57% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.61B | -31.79% | -38.86% | -47.00% | -47.76% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.04B | -78.04% | -72.67% | -59.05% | -50.29% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | 5.08% | 4.88% | 4.58% | 3.44% |
| Cogent Biosciences, Inc. (COGT)vs › | $5.09B | -45.20% | -56.55% | -55.28% | -47.01% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.45B | -9.97% | -20.59% | -24.65% | -22.36% |
ROA
-82.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -2.77% |
| 2024-12-31 | -13.11% |
| 2023-12-31 | -25.27% |
| 2022-12-31 | -38.44% |
| 2021-12-31 | -28.50% |
| 2020-12-31 | -42.87% |
| 2019-12-31 | -35.82% |
| 2018-12-31 | -33.38% |
